Early Treatment of Vulnerable Individuals With Non-Severe SARS-CoV-2 Infection

NCT04920838 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

UNKNOWN

Status

600

Enrollment

OTHER_GOV

Sponsor class

Conditions

Covid19
Covid19 Drug Treatment
Severe Acute Respiratory Syndrome Coronavirus 2
SARS-CoV2 Infection

Interventions

DRUG: Nitazoxanide and Ciclésonide
DRUG: Telmisartan 20Mg Oral Tablet
DRUG: Paracetamol
DRUG: Fluoxétine and Budésonide

Sponsor

ANRS, Emerging Infectious Diseases

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]